
-
2012
Company Description
Symbiomix Therapeutics is a Newark N.J.-based late-stage, privately held biopharmaceutical company
Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women’s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world’s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company’s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
-
Manufacturer:
Science and Engineering -
Formed:
2012 -
Founders:
Robert Jacks -
Company Website:
-
Company E-mail:
-
Company Address:
105 Lock Street, Suite 409Newark, TXUnited States -
CEO:
- Robert Jacks
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits